Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Long-Term Debt Repayments (2016 - 2025)

Fortress Biotech has reported Long-Term Debt Repayments over the past 12 years, most recently at $625000.0 for Q1 2025.

  • Quarterly results put Long-Term Debt Repayments at $625000.0 for Q1 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $625000.0 (down 50.0% YoY), and the annual figure for FY2025 was $625000.0, down 50.0%.
  • Long-Term Debt Repayments for Q1 2025 was $625000.0 at Fortress Biotech, roughly flat from $625000.0 in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for FBIO hit a ceiling of $29.9 million in Q4 2023 and a floor of -$29.9 million in Q3 2023.
  • Median Long-Term Debt Repayments over the past 5 years was $1.4 million (2021), compared with a mean of $3.1 million.
  • Peak annual rise in Long-Term Debt Repayments hit 3788.18% in 2023, while the deepest fall reached 2420.88% in 2023.
  • Fortress Biotech's Long-Term Debt Repayments stood at $5.1 million in 2021, then crashed by 115.77% to -$812000.0 in 2022, then surged by 3788.18% to $29.9 million in 2023, then tumbled by 97.91% to $625000.0 in 2024, then changed by 0.0% to $625000.0 in 2025.
  • The last three reported values for Long-Term Debt Repayments were $625000.0 (Q1 2025), $625000.0 (Q4 2024), and $625000.0 (Q3 2024) per Business Quant data.